Welcome to the Wang Lab

Research Interests

Wang lab's research interest and expertise is using a unique diphtheria toxin resistant yeast Pichia pastoris expression system as a platform to develop diphtheria toxin-based recombinant immunotoxins for cancer treatment and transplantation tolerance induction.

Active Research Projects

CCR4-IL Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-cell Lymphoma
We have developed a CCR4-IL2 bispecific immunotoxin (CCR4-IL2-IT) for targeted therapy of cutaneous T-cell lymphoma (CTCL). CCR4-IL2-IT is genetically engineered to contain both anti-human CCR4 scFv and human IL2 fused to a truncated diphtheria toxin. CCCR4-IL2-IT has demonstrated promising preclinical efficacy in a human CTCL mouse model showing 106% improvement in survival (69 vs. 33.5 days) compared to an IL-2 fusion toxin (Ontak®-like). We have also demonstrated that CCR4-IL2-IT is significantly more effective than FDA-approved Adcetris® (a leading drug in CTCL clinical market) in the same human CTCL mouse model. Recently, we have completed non-GLP toxicology studies of CCR4-IL2-IT in both rats and minipigs with excellent toxicity profile. Currently, Investigational New Drug (IND)-enabling studies of CCR4-IL2-IT are ongoing supported by NCI STTR FastTrack grant, Colorado OEDIT grant and University of Colorado Spark grant. Our goal is to prepare an IND-ready package and move CCR4-IL2-IT into CTCL human clinical trials.    

Bivalent Anti-human CD47 Immunotoxin for Targeted Therapy of T-cell Acute Lymphoblastic Leukemia
We have developed a diphtheria toxin-based bivalent anti-human CD47 immunotoxin (bi-CD47-IT) for targeted therapy of CD47+ cancers. Bi-CD47-IT demonstrated compelling in vivo efficacy in multiple T-cell acute lymphoblastic leukemia (T-ALL) cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models. Bi-CD47-IT significantly prolonged the median survival of the tumor-bearing mice and highly effectively depleted the T-ALL blast cells in the peripheral blood, spleen, liver, bone marrow, brain, and spinal cord in the T-ALL CDX and PDX mouse models. Bi-CD47-IT cured 60% of tumor-bearing mice in a T-ALL Molt-4 CDX mouse model. CD47 is also expressed on normal tissues with low binding avidity, including red blood cells and lymphocytes. Specificity is a concern. We have analyzed the in vitro binding avidity and hemagglutination of bi-CD47-IT in human red blood cells, finding no binding or hemagglutination. We further performed a toxicity study of bi-CD47-IT in humanized mice, which showed that bi-CD47-IT transiently depleted the human lymphocytes. Bi-CD47-IT possesses the “optimal” binding avidity, with effective binding to human CD47+ T-ALL tumor cells, no binding to human red blood cells and weak binding to human lymphocytes. We believe that bi-CD47-IT is a promising and safe therapeutic drug candidate for the targeted therapy of broad-spectrum CD47+ cancers.

CCR4 Immunotoxin for Cancer Immunotherapy via Treg Depletion
Currently no FDA-approved drug specifically and efficiently depletes tumor-infiltrating effector Tregs. CCR4 is highly and specifically expressed on the surface of tumor-infiltrating effector Tregs. CCR4 is one of the recognized targets to deplete tumor-infiltrating effector Tregs. We have developed a diphtheria toxin-based anti-human CCR4 immunotoxin (CCR4-IT) for cancer immunotherapy via Treg depletion. We have demonstrated that CCR4-IT effectively and specifically depleted CCR4+Foxp3+ Tregs in both naïve cynomolgus monkeys and miniature swine. Recent preliminary data demonstrated that combination immunotherapy of CCR4-IT with Pembrolizumab (anti-PD-1 mAb) shows remarkably improved effectiveness compared with Pembrolizumab alone in a cell-line derived xenograft (CDX)-based humanized mouse triple-negative breast cancer (TNBC) model.

Novel CD154 Targeted Therapeutics to Facilitate Vascularized Composite Allotransplantation Tolerance
We have developed a species-specific high-affinity anti-porcine CD154 nanobody using a synthetic nanobody library based-yeast surface display platform. The lack of Fc domain in the anti-porcine CD154 nanobody is expected to reduce off-target effects including thromboembolic side effects. We then genetically engineered the high-affinity anti-porcine CD154 nanobody to truncated diphtheria toxin DT390 to generate a species-specific anti-porcine CD154 immunotoxin. We hypothesize that combination of the depletion of porcine memory alloreactive CD154+ T cells known to interfere with immune tolerance induction using the anti-porcine CD154 immunotoxin with porcine CD40/CD154 co-stimulation blockade using the high-affinity anti-porcine CD154 nanobody will prolong vascularized composite allotransplantation (VCA) graft survival and significantly improve VCA tolerance induction.

Featured Publications

Bivalent CD47 immunotoxin for targeted therapy of T-cell acute lymphoblastic leukemia

11/19/2024

CD47 is overexpressed on the surface of many types of cancer cells, including T-cell acute lymphoblastic leukemia (T-ALL) cells. In this study, we have developed a diphtheria toxin (DT)-based bivalent anti-human CD47 immunotoxin (bi-CD47-IT) for the targeted therapy of CD47+ cancers using a unique DT-resistant yeast Pichia pastoris expression system. Bi-CD47-IT demonstrated compelling in vivo efficacy in multiple...


Toxicology, pharmacokinetics, and immunogenicity studies of CCR4-IL2 bispecific immunotoxin in rats and minipigs

02/15/2024

We have developed a diphtheria toxin-based recombinant human CCR4-IL2 bispecific immunotoxin (CCR4-IL2-IT) for targeted therapy of cutaneous T-cell lymphoma (CTCL). CCR4-IL2-IT demonstrated superior efficacy in an immunodeficient mouse CTCL model. Recently, we have compared the in vivo efficacy of CCR4-IL2-IT versus Brentuximab (FDA approved leading drug in CTCL market) in the same immunodeficient...


CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model

05/15/2023

Cutaneous T-cell lymphoma (CTCL) encompasses two main subtypes: mycosis fungoides and Sezary syndrome. Global response rates for the systemic treatment of mycosis fungoides and Sezary syndrome are approximately 30%, and none of these treatments are thought to be curative. C-C chemokine receptor type 4 (CCR4) and CD25 are encouraging targets for the treatment of CTCL and are individually targeted by mogamulizumab...


A novel diphtheria toxin-based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma

02/04/2021

Epidermal growth factor receptor (EGFR) is often overexpressed in head and neck squamous cell carcinoma (HNSCC) and represents a top candidate for targeted HNSCC therapy. However, the clinical effectiveness of current Food and Drug Administration (FDA)-approved drugs targeting EGFR is moderate, and the overall survival rate for HNSCC patients remains low. Therefore, more effective treatments are urgently needed. In...


Bispecific human IL2-CCR4 immunotoxin targets human cutaneous T-cell lymphoma

03/13/2020

The majority of clinically diagnosed cutaneous T-cell lymphomas (CTCL) highly express the cell-surface markers CC chemokine receptor 4 (CCR4) and/or CD25. Recently, we have developed diphtheria toxin-based recombinant Ontak®-like human IL2 fusion toxin (IL2 fusion toxin) and anti-human CCR4 immunotoxin (CCR4 IT). In this study, we first compared the efficacy of the CCR4 IT vs IL2 fusion toxin for targeting human CD25+ CCR4+ CTCL...


Diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19+ tumors

04/04/2017

CD19 is expressed on normal and neoplastic B cells and is a promising target for immunotherapy. However, there is still an unmet need to further develop novel therapeutic drugs for the treatment of the refractory/relapsing human CD19+ tumors. We have developed a diphtheria toxin-based anti-human CD19 immunotoxin for targeting human CD19+ tumors. We have constructed three isoforms of the CD19 immunotoxin: monovalent...


Treg depletion in non-human primates using a novel diphtheria toxin-based anti-human CCR4 immunotoxin

11/19/2015

Regulatory T cells (Treg) play an important role in modulating the immune response and has attracted increasing attention in diverse fields such as cancer treatment, transplantation and autoimmune diseases. CC chemokine receptor 4 (CCR4) is expressed on the majority of Tregs, especially on effector Tregs. Recently we have developed a diphtheria-toxin based anti-human CCR4 immunotoxin for depleting CCR4(+) cells in vivo. In this...


Porcine Treg depletion with a novel diphtheria toxin-based anti-human CCR4 immunotoxin

10/29/2016

Regulatory T cells (Tregs) are known to play an important role in immunoregulation and have been shown to facilitate induction of transplantation tolerance. Chemokine (C-C motif) receptor 4 (CCR4) is expressed on the surface of effector Tregs involved in controlling alloimmune and autoimmune responses. Recently we have developed a novel diphtheria-toxin based anti-human CCR4 immunotoxin for depleting CCR4+ cells in vivo. In this study...


Diphtheria-toxin based anti-human CCR4 immunotoxin for targeting human CCR4(+) cells in vivo

04/25/2015

CC chemokine receptor 4 (CCR4) has attracted much attention as a promising therapeutic drug target for CCR4(+) tumor cells and Tregs. CCR4 is expressed on some tumor cells such as T-cell acute lymphoblastic leukemia (ALL), adult T-cell leukemia/lymphoma (ATLL), adult peripheral T cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL). CCR4 is also expressed on majority of Tregs, mainly effector Tregs. In this study we have successfully...


Development of a diphtheria toxin based antiporcine CD3 recombinant immunotoxin

09/09/2011

Anti-CD3 immunotoxins, which induce profound but transient T-cell depletion in vivo by inhibiting eukaryotic protein synthesis in CD3+ cells, are effective reagents in large animal models of transplantation tolerance and autoimmune disease therapy. A diphtheria toxin based antiporcine CD3 recombinant immunotoxin was constructed by fusing the truncated diphtheria toxin DT390 with two identical tandem single chain variable...



Surgery

CU Anschutz

Academic Office One

12631 East 17th Avenue

Room: 6111

Aurora, CO 80045


303-724-2750

CMS Login